The hepatocellular carcinoma (HCC) space has been presented with a number of trials exploring immune-oncology (IO) therapies combined with VEGF antibodies, tyrosine kinase inhibitors (TKIs), and more over the past 5 years.
Please refer to the following website for further details:
https://www.targetedonc.com/view/clinical-trial-results-allude-to-new-options-for-patients-with-hcc